<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26721">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885715</url>
  </required_header>
  <id_info>
    <org_study_id>B-1208/168-009</org_study_id>
    <secondary_id>Eunsu Choi</secondary_id>
    <nct_id>NCT01885715</nct_id>
  </id_info>
  <brief_title>Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium</brief_title>
  <official_title>Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to find appropriate dose of neostigmine which is possible to reverse
      rocuronium or cisatracurium till train of four (TOF) 0.9 within 10 minutes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>time to reverse from light muscle relaxation</measure>
    <time_frame>time from TOF 0.5 to TOF 1.0 after injection of different doses of neostigmine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome of this study is how long it takes time to reverse from TOF ratio 0.5 to 1.0 after injection of different doses of neostigmine at the TOF 0.5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to reverse from TOF ratio 0.5 to 0.9</measure>
    <time_frame>time from TOF 0.5 to TOF 0.9 after injection of different doses of neostigmine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome of this study is how long it takes time to reverse from TOF ratio 0.5 to 0.9 after injection of different doses of neostigmine at the TOF 0.5</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Observation of Neuromuscular Block</condition>
  <arm_group>
    <arm_group_label>Rocuronium-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will  measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium-neostigmine 10 ㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium-neostigmine 20 ㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will  measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium-neostigmine 40 ㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisatracurium-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will  measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisatracurium-neostigmine 10 ㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisatracurium-neostigmine 20 ㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisatracurium-neostigmine 40 ㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of neostigmine</intervention_name>
    <description>At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms.</description>
    <arm_group_label>Rocuronium-placebo</arm_group_label>
    <arm_group_label>Rocuronium-neostigmine 10 ㎍</arm_group_label>
    <arm_group_label>Rocuronium-neostigmine 20 ㎍</arm_group_label>
    <arm_group_label>Rocuronium-neostigmine 40 ㎍</arm_group_label>
    <arm_group_label>Cisatracurium-placebo</arm_group_label>
    <arm_group_label>Cisatracurium-neostigmine 10 ㎍</arm_group_label>
    <arm_group_label>Cisatracurium-neostigmine 20 ㎍</arm_group_label>
    <arm_group_label>Cisatracurium-neostigmine 40 ㎍</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist Physical status classification 1 or 2 elective
             surgery under general anesthesia

        Exclusion Criteria:

          -  BMI &gt;25 or &lt; 20 kg/m2

          -  Patients taking intercurrent medication

          -  Glutamic Oxalacetate Transaminase or Glutamic Pyruvate Transaminase &gt; 40 IU/L, Cr &gt;
             1.4 mg/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ah Young Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunsu Choi, professor</last_name>
    <phone>82-31-787-7499</phone>
    <email>potterydoll@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eunsu Choi</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunsu Choi, professor</last_name>
      <phone>82-31-787-7499</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neostigmine</mesh_term>
    <mesh_term>Atracurium</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
